ASCO 2023

The INDIGO study

6 June 2023

During the plenary session, feedback was given by Dr. Pierre Frères of CHU de Liège regarding the INDIGO study presented by Prof. Ingo K. Mellinghoff. This study is a phase 3, double-blinded, global, randomized trial comparing vorasidenib to placebo for patients with an IDH1/2 mutation and residual or recurrent grade 2 glioma. 

See full coverage from ASCO

With the educational support of:

Tags:

Share Article